Jump to content

John D. Hood

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DGG (talk | contribs) at 06:31, 17 February 2020 (rewrite). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

  • Comment: If this draft is accepted, an entry will need to be added to the disambiguation page for the primary name.
    Refer to the subject by his surname as Hood.
    Should he be disambiguated as {scientist) or as (businessman)?
    Does the author of this draft have any sort of financial or other connection with the subject of this draft? Please read the conflict of interest policy and the paid editing policy and make any required declarations.
    You may ask for advice about conflict of interest at the Teahouse.
    If this draft is resubmitted without addressing the question about conflict of interest, it may be Rejected or nominated for deletion. Robert McClenon (talk) 16:24, 5 February 2020 (UTC)
John D. Hood
Alma mater
Scientific career
Institutions[Impact Biomedicines, Inc.

Dr. John D. Hood, an American medical physiologist and pharmacologist, is the Founder and Chief Executive Officer of Impact Biomedicines Inc.[1]

Education and career

Hood received his B.S. in biochemistry and obtained his Ph.D. in medical physiology from Texas A&M University.[2]

Hood started his career as a Director of Research at TargeGen Inc .[3] He was the co-founder and chief scientific officer of Samumed, a private biopharmaceutical company.[4] Now, he is Board Chairman and Co-founder at Endeavor Biomedicines.[5][6][7]

Research

Hood did research on the development of TG101348 for the treatment of JAK2-driven malignancies and found that TG101348 blocked proliferation and colony formation in vitro against cultured and patient-derived cells bearing the JAK2v617F mutations.[8] He also conducted research on tumor regression by targeted gene delivery to the Neovasculature.[9]

Patents

Hood's patents include[10][11] 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof (US9889140B2)[12], Indazole-3-carboxamides and their use as Wnt/beta-catenin signaling pathway inhibitors (US9802916B2)[13], Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof (US9763927B2)[14], β- and γ-diketones and γ-hydroxy ketones as WNT/β-catenin signaling pathway activators (US9884053B2)[15], and 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof (US9855272B2)[16]

Most cited peer-reviewed articles

  • Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nature Reviews Cancer. 2002 Feb;2(2):91-100. According to Google Scholar, this article has been cited 1991 times [17]
  • Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, Cheresh DA. Tumor regression by targeted gene delivery to the neovasculature. Science. 2002 Jun 28;296(5577):2404-7.. According to Google Scholar, this article has been cited 1015 times. [17]
  • Eliceiri BP, Paul R, Schwartzberg PL, Hood JD, Leng J, Cheresh DA. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Molecular cell. 1999 Dec 1;4(6):915-24. . According to Google Scholar, this article has been cited 856 times. [17]
  • Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. American Journal of Physiology-Heart and Circulatory Physiology. 1998 Mar 1;274(3):H1054-8. According to Google Scholar, this article has been cited 828 times. [17]

References

  1. ^ "Jobs with Impact Biomedicines". BioSpace. Retrieved 2019-11-08.
  2. ^ "Bloomberg - Are you a robot?". www.bloomberg.com. Retrieved 2019-11-08. {{cite web}}: Cite uses generic title (help)
  3. ^ "Actavalon Announces Appointment of Dr. John Hood to Its Board of Directors – Actavalon". Retrieved 2019-11-08.
  4. ^ March 26, Amy Duncan | 271sc; 2019. "How John Hood's Determination to Help Patients Turned $20 million into $7 billion". SDEE. Retrieved 2019-11-08. {{cite web}}: |last2= has numeric name (help)CS1 maint: numeric names: authors list (link)
  5. ^ Chen, Caroline (2018-01-09). "How biotech CEO John Hood turned failed Sanofi drug into multibillion deal". https://www.livemint.com. Retrieved 2019-11-08. {{cite web}}: External link in |website= (help)
  6. ^ "SDEE PRESENTS: GET TO KNOW YOUR NEIGHBORS WITH JOHN HOOD". Health Device Network. 2019-02-27. Retrieved 2019-11-08.
  7. ^ 199816 (2018-03-12). "Deep Impact: How Passion, Dedication & Good Science Revived a Life-Saving Drug". WuXi XPress: for WuXi news and R&D insights. Retrieved 2019-11-08. {{cite web}}: |last= has numeric name (help)
  8. ^ Hood, J.; Cao, J.; Chow, C.; Doukas, J.; Hanna, E.; Lohse, D.; Mak, C.; Martin, M.; Stoughton, S.; Tam, B.; Soll, R. (2008-05-20). "Development of TG101348 for the treatment of JAK2-driven malignancies". Journal of Clinical Oncology. 26 (15_suppl): 7083. doi:10.1200/jco.2008.26.15_suppl.7083. ISSN 0732-183X.
  9. ^ Hood, John D.; Bednarski, Mark; Frausto, Ricardo; Guccione, Samira; Reisfeld, Ralph A.; Xiang, Rong; Cheresh, David A. (2002-06-28). "Tumor Regression by Targeted Gene Delivery to the Neovasculature". Science. 296 (5577): 2404–2407. Bibcode:2002Sci...296.2404H. doi:10.1126/science.1070200. ISSN 0036-8075. PMID 12089446.
  10. ^ "John Hood Inventions, Patents and Patent Applications - Justia Patents Search". patents.justia.com. Retrieved 2019-11-08.
  11. ^ pubmeddev (1975). "Error encountered - PubMed - NCBI". Biochemical Pharmacology. 24 (20): 1903–4. doi:10.1016/0006-2952(75)90415-3. PMID 20.
  12. ^ "US9889140B2".{{cite web}}: CS1 maint: url-status (link)
  13. ^ "US9802916B2".{{cite web}}: CS1 maint: url-status (link)
  14. ^ "US9763927B2".{{cite web}}: CS1 maint: url-status (link)
  15. ^ "US9884053B2".{{cite web}}: CS1 maint: url-status (link)
  16. ^ "US9855272B2".{{cite web}}: CS1 maint: url-status (link)
  17. ^ a b c d "Google Scholar author page".{{cite web}}: CS1 maint: url-status (link)
Retrieved from "https://en.wikipedia.org/w/index.php?title=John_D._Hood&oldid=941211605"